PMID- 15791569
OWN - NLM
STAT- MEDLINE
DCOM- 20050505
LR  - 20141120
IS  - 0046-8177 (Print)
IS  - 0046-8177 (Linking)
VI  - 36
IP  - 3
DP  - 2005 Mar
TI  - Assessment of the HER2 status in breast cancer by fluorescence in situ 
      hybridization: a technical review with interpretive guidelines.
PG  - 250-61
AB  - Diagnostic assays for HER2 in breast cancer provide important prognostic 
      information and independently help guide management by identifying patients who 
      are the most likely to benefit from Herceptin-targeted therapy. The biological 
      events underlying HER2 -driven breast cancer that can be assessed in routine 
      clinical specimens include the evaluation of gene amplification by fluorescence 
      in situ hybridization (FISH), enhanced messenger RNA expression by real-time 
      polymerase chain reaction, and the assessment of protein overexpression at the 
      tumor cell membrane by immunohistochemistry (IHC). Immunohistochemistry and FISH 
      methodologies have the advantage of being morphologically driven, allowing for 
      correlations between HER2 expression and morphologic features. However, each has 
      important advantages and disadvantages, which are discussed in detail. Although 
      immunohistochemistry is familiar and readily accommodated in most surgical 
      pathology laboratories, increasing demands for FISH testing in the clinical 
      setting will require greater familiarity with the technical aspects of FISH 
      assays and their interpretation by the greater laboratory community. In this 
      review, we provide an overview of FISH testing for HER2 in breast cancer, with an 
      emphasis on technical considerations, interpretive guidelines, scoring criteria, 
      and quality control. The development of automated platforms for hybridization, 
      image analysis for signal enumeration, and experience with FISH interpretation 
      should broaden the availability of this technology for clinical diagnostic 
      testing.
FAU - Hicks, David G
AU  - Hicks DG
AD  - Department of Anatomic Pathology, The Cleveland Clinic Foundation, Cleveland, OH 
      44195, USA. hicksd4@ccf.org
FAU - Tubbs, Raymond R
AU  - Tubbs RR
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Hum Pathol
JT  - Human pathology
JID - 9421547
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Breast Neoplasms/chemistry/*genetics/pathology
MH  - Cell Nucleus/chemistry
MH  - Cytoplasm/chemistry
MH  - Female
MH  - Gene Expression
MH  - Guidelines as Topic
MH  - Humans
MH  - Immunohistochemistry
MH  - *In Situ Hybridization, Fluorescence/methods
MH  - Quality Control
MH  - Receptor, ErbB-2/analysis/*genetics
RF  - 54
EDAT- 2005/03/26 09:00
MHDA- 2005/05/06 09:00
CRDT- 2005/03/26 09:00
PHST- 2005/03/26 09:00 [pubmed]
PHST- 2005/05/06 09:00 [medline]
PHST- 2005/03/26 09:00 [entrez]
AID - S0046817704006811 [pii]
AID - 10.1016/j.humpath.2004.11.010 [doi]
PST - ppublish
SO  - Hum Pathol. 2005 Mar;36(3):250-61. doi: 10.1016/j.humpath.2004.11.010.